B7-H3 CAR-T (Zhengzhou University)

B7-H3 CAR-T(郑州大学)

Report date: 2026/05/18 20:02:07

Base Information

Drug NameB7-H3 CAR-T (Zhengzhou University)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD276
TargetsCD276 antigen
Therapy Area/IndicationsEsophageal NeoplasmsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesZhengzhou University
China Registration ClassN/A

Develop Information

Active CompaniesZhengzhou University
Inactive CompaniesN/A
Active IndicationsEsophageal NeoplasmsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A